Statistics at a Glance

At a Glance

Estimated New Cases in 2024 299,010

% of All New Cancer Cases 14.9%

Estimated Deaths in 2024 35,250

% of All Cancer Deaths 5.8%

5-Year
Relative Survival

97.5% 2014–2020
Year Rate of New Cases — SEER 8 Rate of New Cases — SEER 12 Death Rate — U.S. 5-Year Relative Survival — SEER 8
Observed Modeled Trend Observed Modeled Trend Observed Modeled Trend Observed Modeled Trend
1975 95.54 96.42 - - 30.97 31.44 67.67% 68.40%
1976 97.57 97.83 - - 31.78 31.72 70.07% 69.24%
1977 100.42 99.26 - - 31.83 32.00 70.69% 70.07%
1978 98.84 100.71 - - 32.66 32.29 71.09% 70.88%
1979 103.13 102.18 - - 32.84 32.58 72.06% 71.67%
1980 105.10 103.68 - - 33.05 32.87 71.87% 72.44%
1981 106.14 105.20 - - 33.17 33.16 73.31% 73.20%
1982 105.52 106.74 - - 33.36 33.46 73.57% 73.94%
1983 108.16 108.30 - - 33.92 33.76 74.31% 74.66%
1984 108.84 109.88 - - 34.06 34.06 74.44% 75.37%
1985 114.17 111.49 - - 33.91 34.36 75.67% 76.06%
1986 117.24 113.12 - - 34.93 34.67 77.94% 76.74%
1987 131.93 126.22 - - 35.11 34.98 81.25% 81.22%
1988 136.56 140.84 - - 35.88 36.14 84.33% 84.92%
1989 143.23 157.14 - - 37.10 37.34 85.48% 87.95%
1990 167.25 175.34 - - 38.56 38.59 89.72% 90.40%
1991 206.43 195.64 - - 39.31 38.92 93.08% 92.38%
1992 225.37 218.29 225.43 222.60 39.22 39.25 96.71% 93.96%
1993 196.27 198.80 197.65 198.73 39.34 39.58 95.51% 95.22%
1994 172.00 181.05 171.42 177.42 38.54 38.17 94.98% 96.23%
1995 162.80 164.89 161.67 158.40 37.29 36.81 95.72% 97.02%
1996 163.02 165.27 161.93 161.37 36.00 35.49 96.81% 97.65%
1997 166.60 165.64 166.90 164.40 34.15 34.23 97.64% 98.15%
1998 161.40 166.02 162.95 167.48 32.63 33.01 98.23% 98.54%
1999 174.71 166.40 173.93 170.62 31.56 31.83 99.18% 98.85%
2000 174.52 166.78 172.59 173.83 30.39 30.69 99.11% 99.10%
2001 177.28 167.17 174.23 171.12 29.52 29.60 100.00% 99.29%
2002 173.75 167.55 171.55 168.47 28.71 28.54 99.76% 99.44%
2003 163.80 167.93 160.88 165.85 27.19 27.52 99.36% 99.56%
2004 160.10 168.32 161.45 163.27 26.19 26.54 99.83% 99.66%
2005 154.43 168.70 152.27 160.73 25.40 25.59 99.55% 99.73%
2006 169.50 169.09 162.12 158.23 24.24 24.68 99.94% 99.79%
2007 170.75 169.47 164.29 155.77 24.23 23.80 99.90% 99.83%
2008 154.35 157.82 150.59 153.35 23.01 22.95 99.22% 99.75%
2009 151.20 146.97 147.29 150.97 22.12 22.13 99.34% 99.62%
2010 142.38 136.86 139.87 138.36 21.83 21.34 99.54% 99.43%
2011 135.42 127.45 133.27 126.80 20.89 20.58 99.21% 99.14%
2012 111.80 118.69 109.83 116.20 19.74 19.84 98.46% 98.70%
2013 108.26 110.53 105.57 106.50 19.52 19.74 98.13% 98.05%
2014 99.55 102.93 97.04 97.60 19.42 19.63 97.50% 97.08%
2015 106.61 106.25 100.86 100.55 19.31 19.53 97.16% 97.33%
2016 109.98 109.68 104.20 103.59 19.82 19.43 98.07% 97.56%
2017 115.80 113.22 109.37 106.72 19.33 19.32 - 97.78%
2018 117.48 116.87 108.87 109.95 19.44 19.22 - 97.97%
2019 121.15 120.64 113.90 113.28 19.03 19.12 - 98.15%
2020 107.22 124.54 101.20 116.70 19.20 19.02 - 98.31%
2021 126.75 128.56 119.13 120.23 18.79 18.92 - 98.46%
2022 - - - - 18.71 18.82 - 98.59%

New cases come from SEER 12. Deaths come from U.S. Mortality.
All Races, Males. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data

New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.


Rate of New Cases and Deaths per 100,000: The rate of new cases of prostate cancer was 116.5 per 100,000 men per year. The death rate was 19.0 per 100,000 men per year. These rates are age-adjusted and based on 2017–2021 cases and 2018–2022 deaths.

Lifetime Risk of Developing Cancer: Approximately 12.8 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID.

Prevalence of This Cancer: In 2021, there were an estimated 3,399,229 men living with prostate cancer in the United States.

Did You Know? Video Series

Survival Statistics

How Many People Survive 5 Years Or More after Being Diagnosed with Prostate Cancer?

Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.

97.5%

5-Year
Relative Survival

97.5%

Based on data from SEER 22 (Excluding IL/MA) 2014–2020. Gray figures represent those who have died from prostate cancer. Green figures represent those who have survived 5 years or more.

Survival by Stage

Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is localized (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is regional or distant. For prostate cancer, 69.4% are diagnosed at the local stage. The 5-year relative survival for localized prostate cancer is 100.0%.

Percent of Cases & 5-Year Relative Survival by Stage at Diagnosis: Prostate Cancer
Stage Percent of Cases 5-Year Relative Survival
Localized
Confined to Primary Site
69% 100.0%
Regional
Spread to Regional Lymph Nodes
13% 100.0%
Distant
Cancer Has Metastasized
8% 36.6%
Unknown
Unstaged
9% 92.3%

SEER 22 (Excluding IL/MA) 2014–2020, All Races, Males by SEER Combined Summary Stage

New Cases and Deaths

How Common Is This Cancer?

Compared to other cancers, prostate cancer is fairly common.

Rank Common Types of Cancer Estimated New
Cases 2024
Estimated
Deaths 2024
1. Breast Cancer (Female) 310,720 42,250
2. Prostate Cancer 299,010 35,250
3. Lung and Bronchus Cancer 234,580 125,070
4. Colorectal Cancer 152,810 53,010
5. Melanoma of the Skin 100,640 8,290
6. Bladder Cancer 83,190 16,840
7. Kidney and Renal Pelvis Cancer 81,610 14,390
8. Non-Hodgkin Lymphoma 80,620 20,140
9. Uterine Cancer 67,880 13,250
10. Pancreatic Cancer 66,440 51,750

Prostate cancer represents 14.9% of all new cancer cases in the U.S.

14.9%

In 2024, it is estimated that there will be 299,010 new cases of prostate cancer and an estimated 35,250 people will die of this disease.

Who Gets This Cancer?

Prostate cancer occurs only in men, and it is more common in older men than younger men. It is more likely to occur in men with a family history of prostate cancer and non-Hispanic Black men. The rate of new cases of prostate cancer was 116.5 per 100,000 men per year based on 2017–2021 cases, age-adjusted.

Rate of New Cases per 100,000 Persons by Race/Ethnicity: Prostate Cancer
Males
All Races 116.5
Hispanic 88.1
Non-Hispanic American Indian/Alaska Native 76.7
Non-Hispanic Asian/Pacific Islander 61.4
Non-Hispanic Black 188.7
Non-Hispanic White 114.9
Females
All Races Sex-specific cancer type
Hispanic
Non-Hispanic American Indian/Alaska Native
Non-Hispanic Asian/Pacific Islander
Non-Hispanic Black
Non-Hispanic White

SEER 22 2017–2021, Age-Adjusted

Percent of New Cases by Age Group: Prostate Cancer
Age Range Percent of New Cases
<20 0.0%
20–34 0.0%
35–44 0.3%
45–54 6.4%
55–64 30.3%
65–74 42.4%
75–84 16.8%
>84 3.8%

Prostate cancer is most frequently diagnosed among men aged 65–74.

Median Age
At Diagnosis

67

SEER 22 2017–2021, All Races, Males

Who Dies From This Cancer?

Because we have screening for prostate cancer, most of the time it is caught before it spreads to other parts of the body. Men who have prostate cancer that is characterized as localized or regional are not as likely to die as men whose cancer is distant. In general prostate cancer has excellent survival rates, but death rates are higher in non-Hispanic Black men, men who have advanced stage cancer, and men who are between the ages of 75 and 84. Prostate cancer is the fifth leading cause of cancer death in the United States. The death rate was 19.0 per 100,000 men per year based on 2018–2022, age-adjusted.

Death Rate per 100,000 Persons by Race/Ethnicity: Prostate Cancer
Males
All Races 19.0
Hispanic 15.4
Non-Hispanic American Indian/Alaska Native 19.4
Non-Hispanic Asian/Pacific Islander 8.8
Non-Hispanic Black 37.2
Non-Hispanic White 18.1
Females
All Races Sex-specific cancer type
Hispanic
Non-Hispanic American Indian/Alaska Native
Non-Hispanic Asian/Pacific Islander
Non-Hispanic Black
Non-Hispanic White

U.S. 2018–2022, Age-Adjusted

Percent of Deaths by Age Group: Prostate Cancer
Age Range Percent of Deaths
<20 0.0%
20–34 0.0%
35–44 0.1%
45–54 1.1%
55–64 8.9%
65–74 24.5%
75–84 33.7%
>84 31.7%

The percent of prostate cancer deaths is highest among men aged 75–84.

Median Age
At Death

79

U.S. 2018–2022, All Races, Males

Trends in Rates

Changes Over Time

Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.

Using statistical models for analysis, age-adjusted rates for new prostate cancer cases have been rising on average 0.9% each year over 2012–2021. Age-adjusted death rates have been falling on average 0.5% each year over 2013–2022. 5-year relative survival trends are shown below.

Interactive Statistics with SEER*Explorer

With SEER*Explorer, you can...
  • Create custom graphs and tables
  • Download data and images
  • Share links to results

SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.

Explore Additional Prostate Cancer Statistics

More About This Cancer

Cancer and the Prostate

Figure: Prostate and Nearby Organs

Figure: Anatomy diagram shows the prostate, urethra, penis, testicle, bladder, lymph nodes, seminal vesicle, and rectum are labeled. An inset provides a close-up view of the prostate, urethra, bladder, seminal vesicles, and rectum.

This cancer forms in tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). The prostate surrounds the urethra, the tube through which urine flows. A healthy prostate is about the size of a walnut. If the prostate grows too large, it squeezes the urethra. This may slow or stop the normal flow of urine. Prostate cancer usually occurs in older men.

Additional Information

More Information

Here are some resources for learning more about prostate cancer.

References

All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.

Suggested Citation

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/prost.html

These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.

The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.

Estimates of new cases and deaths for 2024 are projections made by the American Cancer Society (ACS), based on earlier reported data.

Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.